1Fux L, Ilan N, Sanderson RD, et al. Heparanase: busy at the cell surface[]]. Trends Biochem Sci, 2009, 34(10):51 l-519.
2Cohen-Kaplan V, Naroditsky I, Zetser A, et al. Hep- aranase induces VEGF C and facilitates tumor lymphan- giogenesis[J]. Int J Cancer, 2008, 123(ll):2566-2573.
3Nasser NJ. Heparanase involvement in physiology and dis- ease[J]. Cell Mol Life Sci, 2008, 65(11):1706-1715.
4Sanderson RD, Yang Y, Kelly T, et al. Enzymatic remod- eling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies[J]. J Cell Biochem, 2005, 96(5):897- 905.
5Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis[J]. Int J Biochem Cell Biol, 2006, 38(12): 2018-2039.
6Yang Y, Ren Y, Ramani VC, et al. Heparanase enhanceslocal and systemic osteolysis in multiple myeloma by up- regulating the expression and secretion of RANKL [J]. Cancer Res, 2010, 70(21):8329-8338.
7Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tu- mor progression and metastasis[J]. Nat Med, 1999, 5(7): 793-802.
8Nakaijima M, Irimura T, Di Ferrante D, et al. Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines[J]. Science, 1983, 220(4597):611-613.
9Vreys V, David G. Mammalian heparanase: what is the message[J]? J Cell Mol Med, 2007, 11(3):427-452.
10Doweck I, Kaplan-Cohen V, Naroditsky I, et al. Hep- aranase localization and expression by head and neck cancer: correlation with tumor progression and patient sur- vival[J}. Neoplasia, 2006, 8(12):1055-1061.
4Shih C,Tcichcr BA.Cryptophycins :a novel class of potent antimitoticantitumor dcpsipeptides[J]. Curr Pharm Des, 2001,7(13) : 1259-1276.
5Cohen EE, Rosen F, Stadler WM, et al. Phase Ⅱ trial of ZD18392 in recurrent or metastatic squamous cell carcinoma of the head and neck[J]. J Clin Oncol, 2003,21(10) : 1980-1987.
6Belon J, Irigoyen A, Rodriguez I, et al. Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck [J]. J Clin Oncol,2005, 23(28):515-520.
7Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor actifiity and targets the RAF/MEK/ERK path-wayan d receptortyrosine kinas-esinvolved intumor progressionan dangiogenesis[J]. Cancer Res,2004,64(19) : 7099-7109.
8Ranieri G, PatrunoR, Ruggieri E, et al. Vascular endothelial growth actor as a target ofbevacizumab in cancer: from the biology to the clinic[J]. Curr Med, Chem, 2006,13(16): 1845-1857.
3Liat Fux,Neta Ilan,Ralph D. Sanderson,Israel Vlodavsky.Heparanase: busy at the cell surface[J]. Trends in Biochemical Sciences . 2009 (10)
4Valentina Masola,Maria Francesca Secchi,Giovanni Gambaro,Maurizio Onisto.Heparanase as a Target in Cancer Therapy[J]. Current Cancer Drug Targets . 2014 (3)
5Kishore Sandu,Lluí,s Nisa,Philippe Monnier,Christian Simon,Snezana Andrejevic-Blant,Luc Bron.Clinicobiological progression and prognosis of oral squamous cell carcinoma in relation to the tumor invasive front: impact on prognosis[J]. Acta Oto-Laryngologica . 2014 (4)
6Claudio Pisano,Israel Vlodavsky,Neta Ilan,Franco Zunino.The potential of heparanase as a therapeutic target in cancer[J]. Biochemical Pharmacology . 2014
7Israel Vlodavsky,Renato V. Iozzo,Ralph D. Sanderson.Heparanase: Multiple functions in inflammation, diabetes and atherosclerosis[J]. Matrix Biology . 2013 (5)
8Kiran Jadhav,Nidhi Gupta.Clinicopathological prognostic implicators of oral squamous cell carcinoma: Need to understand and revise[J]. North American Journal of Medical Sciences . 2013 (12)
9Israel Vlodavsky,Phillip Beckhove,Immanuel Lerner,Claudio Pisano,Amichai Meirovitz,Neta Ilan,Michael Elkin.Significance of Heparanase in Cancer and Inflammation[J]. Cancer Microenvironment . 2012 (2)
10Nakajima M,Irimura T,Di Ferrante D,et al.Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science . 1983
